Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
The inactivated poliovirus vaccine (IPV) is used for protection against poliomyelitis in The Netherlands. It is not clear, however, whether IPV vaccination can lead to priming of the mucosal immune system and the induction of IgA. It has been demonstrated that IPV vaccination is able to induce strong memory IgA responses in the serum of persons who have been naturally exposed to wild-type poliovirus. This has led to the hypothesis that IPV vaccination is able to induce poliovirus-specific IgA at mucosal sites in persons who have been previously primed with live poliovirus at mucosal sites. To test this hypothesis, the kinetics of the IgA response in serum and saliva after IPV vaccination were examined in persons previously vaccinated with oral poliovirus vaccine (OPV) or IPV. ELISA and enzyme-linked immunospot assays were used for the detection of poliovirus-specific IgA responses. In addition, B cell populations were separated on the basis of the expression of mucosal (alpha4beta7 integrin) and peripheral homing receptors (L-selectin). Parenteral IPV vaccination was able to boost systemic and mucosal IgA responses in previously OPV-vaccinated persons only. None of the previously vaccinated IPV recipients responded with the production of IgA in saliva. In agreement with this finding, a large percentage of the poliovirus-specific IgA-producing lymphocytes detected in previous OPV recipients expressed the alpha4beta7 integrin. It is concluded that IPV vaccination alone is insufficient to induce a mucosal IgA response against poliovirus. In mucosally (OPV-) primed individuals, however, booster vaccination with IPV leads to a strong mucosal IgA response.
Herremans
T M
TM
Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Tineke.Herremans@rivm.nl
Reimerink
J H
JH
Buisman
A M
AM
Kimman
T G
TG
Koopmans
M P
MP
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D000918:Antibody Specificity; D000921:Antibody-Producing Cells / Q000378:metabolism; D001666:Binding Sites, Antibody; D005243:Feces / Q000737:chemistry; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000096:biosynthesis / Q000097:blood; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D011051:Poliomyelitis / Q000276:immunology*; D017955:Poliovirus / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology*; D012463:Saliva / Q000276:immunology; D012635:Secretory Component / Q000097:blood; D015164:Vaccines, Inactivated / Q000276:immunology
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011054:Poliovirus Vaccine, Inactivated; D012635:Secretory Component; D015164:Vaccines, Inactivated